ギランバレー症候群治療薬市場：治療タイプ、薬剤クラス別、流通チャネル別、地域別、2026～2032年

ギランバレー症候群治療薬市場評価～2026～2032年

ギランバレー症候群（GBS）治療薬市場は、免疫療法の進歩と希少神経疾患に対する認知度の向上が市場を牽引しています。アナリストによると、GBS治療薬市場は2024年の12億米ドルから2032年には20億9,000万米ドルに達すると推定されています。

GBS治療薬市場の急拡大は、世界のGBS発症率の上昇、診断能力の向上、新規治療薬法の研究開発への投資拡大が主要因です。これらの要因により、市場は2026～2032年にかけてCAGR 7.20%で成長します。

ギランバレー症候群治療薬市場定義/概要

ギランバレー症候群は、身体の免疫系が末梢神経系の一部を誤って攻撃する稀な神経疾患です。これにより、急速に筋力が低下し、場合によっては麻痺が生じます。GBS治療薬市場には、この疾患の症状を治療薬・管理するための医薬品が含まれます。

さらに、GBSの主要治療薬は、神経系に対する免疫系の攻撃を軽減し、患者の回復過程をサポートすることに重点が置かれています。これには通常、免疫グロブリン、血漿交換、支持療法が用いられます。さらに、GBSにしばしば伴う疼痛、疲労、抑うつなどの特定の症状を管理するために、さまざまな薬剤が利用されます。

ギランバレー症候群治療薬市場の成長を促進する主要因は何か？

ギランバレー症候群の世界の発生頻度の増加が、より良い治療薬を求める主要原動力となっています。世界保健機関（WHO）は、ギランバレー症候群は毎年人口10万人あたり1～2人が罹患し、世界中で合計10万人以上が罹患すると推定しています。GBS患者の増加により、免疫グロブリンやプラズマフェレーシスなどの治療薬が必要とされています。

免疫グロブリン（IVIg）療法はGBSの最も効果的な治療薬法として登場し、その人気の高まりが市場拡大に拍車をかけています。2020年、米国立衛生ラボ（NIH）は、先進国のGBS症例の80％以上でIVIg療法が使用されていると発表しました。この治療薬の広範な使用が、市場における免疫グロブリン製剤の需要を押し上げています。

さらに、GBSの早期発見のための診断ツールの改善により、治療薬がより迅速に提供されるようになり、市場の推進力となっています。欧州神経学会連合（EFNS）の報告によると、電気生理学的検査と脳脊髄液分析の進歩により、GBSの診断精度は近年70％以上向上しています。早期かつ正確な診断は、効果的な治療薬を行う上で極めて重要であり、GBS治療薬の需要を牽引しています。

ギランバレー症候群治療薬の市場導入に影響を与える主要課題は？

ギランバレー症候群治療薬の採用にはいくつかの課題があり、そのひとつが治療薬費の高さです。GBSの主要治療薬法である免疫グロブリン療法は、ヒト血漿から免疫グロブリン製剤を得るという複雑な製造プロセスを伴うため、高額になる傾向があります。これは、特に先進ヘルスケア治療薬へのアクセスが限られている中低所得地域の患者にとって障壁となります。また、高額な治療薬費はヘルスケアを圧迫し、これらの重要な治療薬法を広く利用できるようにすることや、手ごろな価格で提供することを難しくしています。

もうひとつの大きな課題は、特定の地域で有効な治療薬法が限られていることです。免疫グロブリン療法とプラズマフェレシスはGBSの標準治療薬と考えられているが、これらの治療薬へのアクセスはすべての国で一様ではないです。ヘルスケアインフラが未発達な地域では、これらの治療薬の不足や治療薬の遅れが生じ、患者の予後に悪影響を及ぼしています。さらに、免疫グロブリンは他の自己免疫疾患や神経疾患にも使用されているため、世界の需要が高まっており、供給の制約を招き、GBS患者に影響を及ぼしています。

さらに、ギランバレー症候群は診断が複雑であるため、タイムリーな薬剤導入が課題となっています。GBSは希少疾患であり、急速に進行するため、効果的な治療薬を行うためには早期診断が重要です。しかし、筋力低下や麻痺などの症状は他の神経疾患に類似しているため、ヘルスケア提供者にとって診断は困難です。GBSの発見が遅れると、免疫グロブリン製剤やプラズマフェレーシスによる適時治療薬の機会を逃すことになり、利用可能な治療薬法の全体的な有効性が制限され、患者の転帰を悪化させる可能性があります。このような診断上の課題も、市場におけるGBS治療薬の普及を妨げています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ギランバレー症候群治療薬の競合市場：薬剤クラス別

• 免疫グロブリン
• 抗けいれん薬
• 抗うつ薬
• 非ステロイド性抗炎症薬
• オピオイド
• その他

第5章 ギランバレー症候群治療薬の競合市場：治療タイプ別

• 免疫グロブリン静注療法
• 血漿交換
• 支持療法

第6章 ギランバレー症候群治療薬の競合市場：流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Grifols S.A.
• CSL Behring
• Shire（現Takeda Pharmaceutical Company傘下）
• Octapharma AG
• Nihon Pharmaceutical Co., Ltd.
• Akari Therapeutics, Plc
• Hansa Biopharma AB
• BIoTest AG
• China Biologic Products Holdings, Inc.
• Kedrion Biopharma Inc.

第11章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 供給源と参考文献

Guillain Barre Syndrome Drugs Market Valuation - 2026-2032

The Guillain Barre Syndrome (GBS) drugs market is driven upwards by advancements in immunotherapy and increasing awareness of rare neurological disorders. According to analysts, the GBS drugs market is estimated to reach a valuation of USD 2.09 Billion by 2032, up from USD 1.20 Billion in 2024.

The rapid expansion of the GBS drugs market is primarily driven by the rising global incidence of GBS, improving diagnostic capabilities, and growing investment in research and development of novel therapies. These factors are enabling the market to grow at a CAGR of 7.20 % from 2026 to 2032.

Guillain Barre Syndrome Drugs Market: Definition/Overview

Guillain-Barre Syndrome (GBS) is a rare neurological disorder in which the body's immune system mistakenly attacks part of its peripheral nervous system. This leads to rapid-onset muscle weakness and, in some cases, paralysis. The GBS drugs market encompasses pharmaceutical products used to treat and manage the symptoms of this condition.

Furthermore, the primary treatments for GBS are focused on reducing the immune system's attack on the nervous system and supporting patients through the recovery process. This is typically achieved using immunoglobulins, plasma exchange, and supportive care. Additionally, various drugs are utilized to manage specific symptoms such as pain, fatigue, and depression that often accompany GBS.

What are the Key Drivers Propelling the Growth of the Guillain Barre Syndrome Drugs Market?

The increased global frequency of Guillain-Barre Syndrome is a primary driving force behind the quest for better treatments. The World Health Organization (WHO) estimates that GBS affects 1 to 2 persons per 100,000 people each year, totaling more than 100,000 cases worldwide. The increasing incidence of GBS cases necessitates treatments such as immunoglobulins and plasmapheresis.

Immunoglobulin (IVIg) therapy has emerged as the most effective treatment for GBS, and its growing popularity is fueling market expansion. In 2020, the National Institutes of Health (NIH) stated that IVIg therapy was used in more than 80% of GBS cases in developed countries. The extensive usage of this treatment is driving up demand for immunoglobulin goods in the market.

Furthermore, improved diagnostic tools for early detection of GBS have led to more prompt delivery of treatments, propelling the market. The European Federation of Neurological Societies (EFNS) reports that advances in electrophysiological testing and cerebrospinal fluid analysis have enhanced GBS diagnostic accuracy by more than 70% in recent years. Early and precise diagnosis is crucial for giving effective therapies, which drives demand for GBS medicines.

What are the Key Challenges Impacting the Adoption of Guillain Barre Syndrome Drugs in the Market?

The adoption of Guillain-Barre Syndrome (GBS) drugs faces several challenges, one of which is the high cost of treatment. Immunoglobulin therapies, which are the primary treatment for GBS, tend to be expensive due to the complex production process involved in deriving these products from human plasma. This creates barriers for patients, especially in low- and middle-income regions, where access to advanced healthcare treatments is limited. The high cost also puts pressure on healthcare systems, making it difficult to ensure the widespread availability and affordability of these critical treatments.

Another significant challenge is the limited availability of effective treatments in certain regions. While immunoglobulin therapies and plasmapheresis are considered the standard of care for GBS, access to these treatments is not uniform across all countries. In regions with underdeveloped healthcare infrastructures, there are shortages of these drugs or delays in treatment, which negatively affect patient outcomes. Additionally, the global demand for immunoglobulins has risen due to their use in other autoimmune and neurological disorders, leading to supply constraints and impacting GBS patients.

Furthermore, the diagnostic complexity of Guillain-Barre Syndrome poses a challenge to timely drug adoption. GBS is a rare and rapidly progressing condition, and early diagnosis is crucial for effective treatment. However, its symptoms-such as muscle weakness and paralysis-mimic other neurological conditions, making diagnosis difficult for healthcare providers. Delays in identifying GBS result in missed opportunities for timely treatment with immunoglobulins or plasmapheresis, limiting the overall efficacy of the available therapies and potentially worsening patient outcomes. These diagnostic challenges also hinder the overall uptake of GBS-specific drugs in the market.

Category-Wise Acumens

What are the Drivers that Contribute to the Demand for Intravenous Immunoglobulin?

The intravenous immunoglobulin (IVIG) segment is estimated to dominate the market in the treatment type category during the forecast period. IVIG therapy is widely recognized as a first-line treatment for GBS due to its effectiveness in rapidly modulating the immune response. The ability of IVIG to reduce the severity and duration of GBS symptoms is making it a preferred choice among healthcare providers.

The relatively lower risk profile of IVIG compared to plasma exchange is also contributing to its dominance. IVIG treatment is associated with fewer complications and is generally better tolerated by patients, particularly those who are critically ill or have contraindications to plasma exchange.

Furthermore, the convenience of IVIG administration is noted as a factor driving its preference. The therapy is given in outpatient settings, reducing the need for prolonged hospital stays. This aspect is not only improving patient comfort but also potentially reducing overall treatment costs, making IVIG an attractive option for both patients and healthcare systems.

What are the Potential Factors for the Growth of Immunoglobulins in the Market?

The immunoglobulins segment is estimated to dominate the GBS drugs market in the drug class category during the forecast period. The proven efficacy of immunoglobulins in GBS treatment is the primary driver of this dominance. These drugs are + shown to effectively reduce the immune system's attack on the nervous system, leading to faster recovery and improved outcomes for patients.

The versatility of immunoglobulins in treating various autoimmune and inflammatory conditions is also contributing to their market leadership. The wide range of applications is driving increased production and availability of these drugs, potentially leading to economies of scale and improved accessibility for GBS patients.

Furthermore, ongoing research is conducted into novel formulations and administration methods for immunoglobulins. These innovations are aimed at enhancing efficacy, reducing side effects, and improving patient convenience. Such advancements are expected to further solidify the position of immunoglobulins in the GBS drugs market.

What are the Key Factors that Contribute to North America's Edge in the Market?

According to VMR Analyst, North America is estimated to dominate the Guillain barre syndrome drugs market during the forecast period. The growing prevalence of Guillain-Barre Syndrome in North America significantly drives the demand for effective treatments, including immunoglobulins and plasmapheresis. According to the Centers for Disease Control and Prevention (CDC), GBS affects approximately 3,000 to 6,000 people in the United States each year. The consistently high incidence rate of GBS fosters a robust market for therapies in the region.

The correlation between Zika virus infections and the onset of GBS has contributed to a growing demand for treatment options. In 2016, the CDC reported a surge in Zika virus infections in the United States and its territories, particularly in Florida, Puerto Rico, and Texas. In Puerto Rico alone, there were 61 confirmed cases of GBS linked to Zika virus infection. The spread of Zika and its association with GBS have heightened the demand for effective therapies.

Furthermore, North America's advanced healthcare infrastructure and support for rare disease research have accelerated the development of GBS treatments. In 2020, the National Institutes of Health (NIH) allocated more than $1.5 billion for neurological disorder research, which includes funding for rare diseases like GBS. This strong financial backing and institutional support drive innovations in GBS treatments, expanding the availability of drugs for patients.

How Do Government Initiatives Shape the Market Landscape in Europe?

Europe is estimated to exhibit significant growth within the GBS drugs market during the forecast period. Europe has witnessed a rising incidence of autoimmune disorders, including Guillain-Barre Syndrome, which drives the demand for treatments like immunoglobulins. According to a 2022 report from the European Academy of Neurology (EAN), approximately 1 to 2 individuals per 100,000 are diagnosed with GBS annually across Europe, translating to nearly 10,000 new cases each year. This increasing incidence boosts the demand for effective therapies.

Europe has seen a correlation between influenza outbreaks and the onset of GBS, prompting increased use of immunoglobulins and other therapies. According to the European Centre for Disease Prevention and Control (ECDC), influenza vaccines in 2021-2022 were linked to a 7% rise in GBS cases in some regions due to complications. The strong connection between influenza and GBS drives the need for accessible GBS treatments, particularly during the flu season.

Furthermore, European governments have prioritized rare diseases like GBS through various initiatives, driving the research and availability of treatments. The European Union's Orphan Drug Regulation has incentivized drug development for rare diseases since 2000. As of 2022, over 200 orphan medicinal products have been approved for rare diseases, including GBS, providing a significant boost to the GBS drugs market.

Competitive Landscape

The Guillain barre syndrome drugs market's competitive landscape is characterized by a varied range of large pharmaceutical companies and smaller specialized firms focusing on rare neurological disorders.

Some of the prominent players operating in the guillain barre syndrome drugs market include:

Grifols S.A.

CSL Behring

Shire (now part of Takeda Pharmaceutical Company)

Octapharma AG

Nihon Pharmaceutical Co., Ltd.

Akari Therapeutics, Plc

Hansa Biopharma AB

Biotest AG

China Biologic Products Holdings, Inc.

Kedrion Biopharma Inc.

Latest Developments

In July 2023, Grifols, a global leader in immunoglobulin therapies, announced a strategic partnership with the European Neurological Society to advance research on Guillain-Barre Syndrome (GBS) treatments. This collaboration aims to support clinical trials focusing on the efficacy of intravenous immunoglobulins (IVIg) in managing GBS symptoms and improving patient outcomes. The partnership is expected to accelerate the availability of enhanced GBS therapies across Europe.

In March 2022, Octapharma, a leading pharmaceutical company, launched a new clinical trial for its human plasma-derived immunoglobulin product in Europe, targeting patients with GBS. This trial is focused on evaluating the long-term benefits of IVIg treatments in reducing recovery time for GBS patients. Octapharma's trial is part of its broader strategy to expand its GBS drug portfolio in Europe.

Guillain Barre Syndrome Drugs Market, By Category

• Treatment Type:
• Intravenous Immunoglobulin
• Plasma Exchange
• Supportive Care
• Drug Class:
• Immunoglobulins
• Anticonvulsants
• Antidepressants
• NSAIDs
• Opioids
• Others
• Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Guillain-Barre Syndrome Drugs Competitive Market, By Drug Class

• Immunoglobulins
• Anticonvulsants
• Antidepressants
• NSAIDs
• Opioids
• Others

5. Guillain-Barre Syndrome Drugs Competitive Market, By Treatment Type

• Intravenous Immunoglobulin
• Plasma Exchange
• Supportive Care

6. Guillain-Barre Syndrome Drugs Competitive Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Grifols S.A.
• CSL Behring
• Shire (now part of Takeda Pharmaceutical Company)
• Octapharma AG
• Nihon Pharmaceutical Co., Ltd.
• Akari Therapeutics, Plc
• Hansa Biopharma AB
• Biotest AG
• China Biologic Products Holdings, Inc.
• Kedrion Biopharma Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References